Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Assets: 2019-2025

Historic Current Assets for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $440.6 million.

  • Nurix Therapeutics' Current Assets fell 3.39% to $440.6 million in Q3 2025 from the same period last year, while for Aug 2025 it was $440.6 million, marking a year-over-year decrease of 3.39%. This contributed to the annual value of $619.4 million for FY2024, which is 109.60% up from last year.
  • As of Q3 2025, Nurix Therapeutics' Current Assets stood at $440.6 million, which was down 14.50% from $515.3 million recorded in Q2 2025.
  • Over the past 5 years, Nurix Therapeutics' Current Assets peaked at $619.4 million during Q4 2024, and registered a low of $251.0 million during Q1 2024.
  • Moreover, its 3-year median value for Current Assets was $440.6 million (2025), whereas its average is $403.5 million.
  • In the last 5 years, Nurix Therapeutics' Current Assets dropped by 24.49% in 2023 and then skyrocketed by 124.61% in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Current Assets stood at $311.1 million in 2021, then grew by 2.36% to $318.4 million in 2022, then fell by 7.21% to $295.5 million in 2023, then spiked by 109.60% to $619.4 million in 2024, then decreased by 3.39% to $440.6 million in 2025.
  • Its Current Assets was $440.6 million in Q3 2025, compared to $515.3 million in Q2 2025 and $563.7 million in Q1 2025.